Which States Still Cover GLP-1s for Weight Loss Under Medicaid? (2026 Map)
Medicaid coverage for GLP-1 weight-loss medications is a patchwork — and it got worse in 2026. Several states eliminated coverage entirely, while others maintain it with significant restrictions. As of June 2026, only about 13 states cover GLP-1s for obesity under Medicaid.
Here's the state-by-state reality.
States That Eliminated Coverage in 2026
These states have discontinued Medicaid coverage of GLP-1 medications when prescribed solely for weight loss (coverage for type 2 diabetes continues):
- California (Medi-Cal) — Effective January 1, 2026, for members age 21+
- Pennsylvania — Effective January 1, 2026, for all weight-loss indications
- New Hampshire — NH Healthy Families discontinued coverage January 1, 2026
- South Carolina — Coverage eliminated for obesity treatment
If you were already receiving GLP-1 medications through Medicaid in these states, you may have been eligible for continuation during a transition period. In California, members who requested a State Hearing within 10 days of their denial notice could continue receiving medication pending the hearing decision.
States That Still Cover (With Restrictions)
Coverage varies significantly by state. Most states that cover GLP-1s for weight loss require:
- Prior authorization with BMI documentation
- Evidence of failed lifestyle interventions (3–6 months)
- Prescriber attestation of medical necessity
- Periodic recertification (every 6–12 months)
Some states have raised BMI thresholds. For example, certain Blue Shield of California commercial plans (non-Medicaid) now require BMI ≥ 40 for new GLP-1 starts.
The Diabetes Pathway
All state Medicaid programs cover GLP-1 medications for type 2 diabetes. If you have both obesity and T2D, your physician may be able to prescribe Ozempic or Mounjaro under the diabetes indication — which is covered regardless of state weight-loss exclusions.
This isn't a loophole; it's legitimate medical practice. GLP-1s were originally developed for diabetes and remain first-line treatments for T2D.
Cash-Pay Alternatives for Medicaid Patients
If your state has eliminated Medicaid coverage for weight loss, compounded semaglutide through licensed telehealth platforms offers the most affordable alternative, typically $130–$200/mo.